Ras

Cat. No.

A63563

CAS No.

195981-08-9

BMS-214662 hydrochloride

BMS-214662 hydrochloride is a potent farnesyltransferase inhibitor that disrupts the prenylation of Ras proteins, preventing their localization and function at the cell membrane. This inhibition leads to significant anti-tumor activity, making it a valuable tool for cancer research. The compound demonstrates a high affinity for H-Ras with an IC50 of 1.3 nM and for K-Ras with an IC50 of 8.4 nM, highlighting its potential in studying tumorigenesis associated with Ras signaling pathways.

Cat. No.

A63565

CAS No.

2621928-53-6

KRAS G12D inhibitor 5

KRAS G12D inhibitor 5 is a selective inhibitor targeting the mutated KRAS G12D protein, a key driver in various malignancies, including pancreatic cancer. This compound is valuable in research applications focusing on the therapeutic mechanisms underlying KRAS-driven tumorigenesis and may help elucidate the pathways involved in cancer progression and resistance.

Cat. No.

A63566

CAS No.

2839563-01-6

Sosimerasib

Sosimerasib is an orally active inhibitor targeting KRAS G12C mutations. It exhibits significant functional inhibitory effects on mutant KRAS G12C proteins, making it a valuable tool for studying signaling pathways involved in cancer progression. This compound is particularly relevant for research applications focused on non-small cell lung cancer.

Cat. No.

A63567

CAS No.

2621927-57-7

MRTX-EX185

MRTX-EX185 is a selective inhibitor of KRAS(G12D) with an IC50 of 90 nM, effectively binding to both GDP-loaded and active GTP-bound states of KRAS. This compound demonstrates broad-spectrum activity against various KRAS mutations, including KRAS WT, KRAS (G12C), KRAS (Q61H), and KRAS (G13D), with IC50 values ranging from 110 nM to 290 nM. Additionally, MRTX-EX185 interacts with GDP-loaded HRAS. This reagent is valuable for investigating RAS-driven tumors, particularly in the context of pancreatic cancer research.

Cat. No.

A63568

CAS No.

2946593-60-6

(R)-G12Di-7

(R)-G12Di-7 is a covalent inhibitor specifically targeting K-Ras-G12D. This compound selectively binds to the K-Ras-G12D·GDP and K-Ras-G12D·GppNHp complexes, effectively labeling them. (R)-G12Di-7 demonstrates significant inhibitory activity against cancer cells harboring the G12D mutation, making it a valuable tool for research into K-Ras-related oncogenic signaling and potential therapeutic interventions.

Cat. No.

A63569

CAS No.

2706637-12-7

(7R)-Elisrasib

Synonyms: (7R)-D3S-001

(7R)-Elisrasib is a selective inhibitor targeting the KRASG12C mutation, a key driver in various cancers. This compound demonstrates potent antitumor activity, effectively inhibiting tumor growth in preclinical mouse models. It is primarily used in cancer research focused on KRAS-driven tumors and aids in the investigation of targeted therapies for oncogenic mutations.

Cat. No.

A63570

CAS No.

2649004-88-4

KRAS G12C inhibitor 28

KRAS G12C inhibitor 28 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 of 57 nM. This compound demonstrates significant antitumor activity and is utilized in research focusing on KRAS-driven cancers. Its applications include investigating the therapeutic potential of KRAS inhibition in various oncological studies.

Cat. No.

A63571

CAS No.

2252242-32-1

RAS GTPase inhibitor 1

RAS GTPase inhibitor 1 is a specific inhibitor targeting RAS GTPase, known for its significant anti-tumor activity. This compound demonstrates an effective EC50 of less than 1 μM in facilitating nucleotide exchange and an IC50 of less than 1 μM in H727 cancer cells. It is valuable for research applications aimed at understanding RAS signaling pathways and developing targeted cancer therapies.

Cat. No.

A63572

CAS No.

2376328-55-9

K-Ras G12C-IN-4

K-Ras G12C-IN-4 is a potent covalent inhibitor targeting the KRAS G12C mutation. This compound effectively disrupts the oncogenic signaling pathways associated with mutant KRAS, making it a valuable tool in cancer research. Its application extends to studying therapeutic approaches for tumors harboring KRAS G12C mutations, providing insights into potential treatment strategies.

Cat. No.

A63573

CAS No.

2972625-49-1

KRAS G12D inhibitor 26

KRAS G12D inhibitor 26 is a specific inhibitor targeting the KRAS(G12D) mutation, with an IC50 of ≤ 100 nM. This compound modulates KRAS signaling pathways, making it a valuable tool for studying KRAS-related oncogenic processes. Its application is pivotal in cancer research, particularly in elucidating the mechanisms underlying tumorigenesis and therapeutic resistance in KRAS-driven malignancies.

Cat. No.

A63574

CAS No.

306969-25-5

p67phox-IN-1

p67phox-IN-1 is a specific inhibitor of the interaction between Rac GTPase and the p67phox protein. This compound interferes with the activation of the NADPH oxidase complex, thereby modulating reactive oxygen species production. p67phox-IN-1 serves as a valuable tool in research related to oxidative stress, inflammation, and redox signaling pathways. Its utility extends to studies exploring the role of Rac GTPases in various physiological and pathological processes.

Cat. No.

A63575

CAS No.

2070916-70-8

PPI-GIT1/β-Pix PPI-IN-1

PPI-GIT1/β-Pix PPI-IN-1 is a potent inhibitor of the GIT1/β-Pix protein-protein interaction, exhibiting a KD value of 7.7 µM. By disrupting the GIT/PIX interaction, this compound effectively modulates the activation of downstream Rho GTPases Rac1 and Cdc42, which are critical in various signaling pathways. PPI-GIT1/β-Pix PPI-IN-1 is particularly relevant in cancer research, demonstrating significant inhibitory effects on the metastasis of gastric cancer.

Cat. No.

A63577

CAS No.

2621928-43-4

KRAS G12D inhibitor 1

KRAS G12D Inhibitor 1 is a potent inhibitor targeting the KRAS G12D mutant with an IC50 of 0.4 nM. It effectively inhibits KRAS G12D-mediated ERK phosphorylation, exhibiting an IC50 of 0.8 nM. This compound is valuable in research focused on cancers driven by KRAS G12D mutations, including pancreatic ductal adenocarcinoma and colorectal cancer.

Cat. No.

A63579

CAS No.

3081520-70-6

(R)-KRAS G12D inhibitor 28 hydrochloride dihydrate

(R)-KRAS G12D inhibitor 28 hydrochloride dihydrate specifically targets the KRAS G12D mutant protein, functioning as an effective inhibitor. This compound demonstrates significant potential in cancer research, particularly in studies focused on KRAS-driven malignancies. Its application can aid in the investigation of KRAS signaling pathways and the development of targeted therapies for KRAS-related tumors.

Cat. No.

A63580

CAS No.

2409131-50-4

KRASG12C IN-13

KRASG12C IN-13 is a selective inhibitor targeting the KRAS G12C mutation. This compound demonstrates significant biological activity against advanced solid tumors, particularly non-small cell lung cancer and colorectal cancer. Researchers can utilize KRASG12C IN-13 to investigate therapeutic strategies and resistance mechanisms associated with KRAS-driven malignancies.

Cat. No.

A63581

CAS No.

2042365-85-3

Kras4B G12D-IN-1

Kras4B G12D-IN-1 is a selective inhibitor of the Kras4B G12D mutant, targeting its oncogenic activity. This compound demonstrates significant anticancer properties by reducing Kras protein expression in mouse embryonic fibroblasts (MEF) harboring the Kras4B G12D mutation. Kras4B G12D-IN-1 is relevant for research investigating Kras-driven cancers and the development of targeted therapies.

Cat. No.

A63582

CAS No.

3033638-63-7

KRASG12D-IN-3

KRASG12D-IN-3 is a potent inhibitor that specifically targets the KRASG12D mutation. It demonstrates significant anti-proliferative effects on AGS and AsPC-1 cell lines, with IC50 values of 0.38 nM and 1.23 nM, respectively. This compound is valuable for research applications focused on the role of KRAS mutations in cancer biology and therapeutic development.

Cat. No.

A63584

CAS No.

2561529-96-0

MRTX849 acid

MRTX849 acid serves as a ligand for KRAS G12C, facilitating the synthesis of the PROTAC LC-2. This first-in-class PROTAC effectively induces degradation of endogenous KRAS G12C, demonstrating potent biological activity with DC50 values ranging from 0.25 to 0.76 μM. It is applicable in research settings focused on targeted protein degradation and cancer therapeutics.

Cat. No.

A63585

CAS No.

3105153-34-9

IACS-56676

IACS-56676 is a selective inhibitor of the NRAS G12D mutation, with a binding affinity (Kd) of 0.031 μM. It stabilizes the p-loop and preserves critical interactions with key residues, including Asp12, Gly60, and Asp69, allowing for its specificity toward NRAS G12D while sparing wild-type KRAS through targeting Leu95. This compound is applicable in research focusing on melanoma, hematologic malignancies, and thyroid cancer, providing a valuable tool for investigating targeted therapies in these contexts.

Cat. No.

A63586

CAS No.

2893809-52-2

(4R)-BBO-8520

(4R)-BBO-8520 is a selective inhibitor of the KRAS G12C mutant. This compound effectively impedes the KRAS G12C (ON) signaling, thereby inhibiting cell proliferation by blocking the interaction with GTP. Additionally, (4R)-BBO-8520 disrupts the RAS-RAF1 interaction, facilitating the return of KRAS G12C to its inactive (OFF) state. It is particularly valuable for research applications focused on cancer biology and therapeutics targeting KRAS-driven malignancies.

Cat. No.

A63588

CAS No.

24527-27-3

Spiclomazine

Synonyms: Clospirazine

Spiclomazine is a selective inhibitor of mutant KRAS(G12C), targeting KRAS-driven pancreatic cancer. This compound effectively reduces KRas-GTP levels and inhibits downstream RAS-mediated signaling pathways. In preclinical studies, Spiclomazine demonstrates significant tumor progression inhibition in mouse renal capsule xenotransplantation models, making it a valuable tool for researching therapeutic strategies against KRAS-driven malignancies.

Cat. No.

A63590

CAS No.

17670-19-8

6-Thio-GTP

Synonyms: 6-Thioguanosine-5'-triphosphate

6-Thio-GTP is a GTP analogue that serves as a metabolite of the immunosuppressive agent Azathioprine. This nucleotide analogue is significant for its ability to interfere with nucleotide metabolism and modulate cellular signaling pathways. Its applications extend to studies on nucleic acid synthesis, signal transduction, and immune response regulation in various biological systems.

Cat. No.

A63591

CAS No.

1588388-60-6

FAM49B (190-198) mouse

FAM49B (190-198) mouse is a peptide fragment targeting FAM49B, a mitochondria-localized protein involved in the regulation of mitochondrial fission. This peptide plays a critical role in maintaining mitochondrial function and integrity while influencing tumor progression. Additionally, FAM49B serves as a negative regulator of T cell activation by inhibiting GTPase Rac activity and modulating cytoskeletal organization, making it a valuable tool for research in cancer biology and immunology.

Cat. No.

A63592

CAS No.

57717-97-2

(+)-Perillyl alcohol ((R)-(+)-Perillyl alcohol)

Synonyms: (R)-(+)-Perillyl alcohol

(+) - Perillyl alcohol is the S-(-) enantiomer known for its ability to inhibit polypeptide growth and impede the cell cycle at the G0/G1 phase. This compound modulates cellular signaling pathways linked to alterations in cytoskeletal actin organization. Additionally, (+)-Perillyl alcohol results in decreased expression of key regulatory proteins, including Ras and CDC2 kinase, making it a valuable reagent for studies in cell biology and cancer research.

Cat. No.

A63593

CAS No.

3044773-77-2

K-Ras-IN-4

K-Ras-IN-4 is a potent K-Ras inhibitor that specifically targets the K-Ras oncogene, a critical player in cancer cell signaling. This compound effectively impedes K-Ras-mediated signaling pathways, thereby attenuating cell proliferation and survival in K-Ras-driven tumors. K-Ras-IN-4 is utilized in research focused on understanding K-Ras biology and developing targeted therapies for cancers associated with K-Ras mutations.